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Abstract
Background Myopalladin (MYPN) is a striated muscle-specific, immunoglobulin-containing protein located in the Z-line and I-
band of the sarcomere as well as the nucleus. Heterozygous MYPN gene mutations are associated with hypertrophic, dilated,
and restrictive cardiomyopathy, and homozygous loss-of-function truncating mutations have recently been identified in pa-
tients with cap myopathy, nemaline myopathy, and congenital myopathy with hanging big toe.
Methods Constitutive MYPN knockout (MKO) mice were generated, and the role of MYPN in skeletal muscle was studied
through molecular, cellular, biochemical, structural, biomechanical, and physiological studies in vivo and in vitro.
Results MKO mice were 13% smaller compared with wild-type controls and exhibited a 48% reduction in myofibre cross-
sectional area (CSA) and significantly increased fibre number. Similarly, reduced myotube width was observed in MKO primary
myoblast cultures. Biomechanical studies showed reduced isometric force and power output in MKO mice as a result of the
reduced CSA, whereas the force developed by each myosin molecular motor was unaffected. While the performance by tread-
mill running was similar in MKO and wild-type mice, MKO mice showed progressively decreased exercise capability, Z-line dam-
age, and signs of muscle regeneration following consecutive days of downhill running. Additionally, MKO muscle exhibited
progressive Z-line widening starting from 8 months of age. RNA-sequencing analysis revealed down-regulation of serum re-
sponse factor (SRF)-target genes in muscles from postnatal MKO mice, important for muscle growth and differentiation. The
SRF pathway is regulated by actin dynamics as binding of globular actin to the SRF-cofactor myocardin-related transcription
factor A (MRTF-A) prevents its translocation to the nucleus where it binds and activates SRF. MYPN was found to bind and bun-
dle filamentous actin as well as interact with MRTF-A. In particular, while MYPN reduced actin polymerization, it strongly
inhibited actin depolymerization and consequently increased MRTF-A-mediated activation of SRF signalling in myogenic cells.
Reduced myotube width in MKO primary myoblast cultures was rescued by transduction with constitutive active SRF, demon-
strating that MYPN promotes skeletal muscle growth through activation of the SRF pathway.
Conclusions Myopalladin plays a critical role in the control of skeletal muscle growth through its effect on actin dynamics and
consequently the SRF pathway. In addition, MYPN is important for the maintenance of Z-line integrity during exercise and ag-
ing. These results suggest that muscle weakness in patients with biallelic MYPN mutations may be associated with reduced
myofibre CSA and SRF signalling and that the disease phenotype may be aggravated by exercise.
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Introduction
Myopalladin (MYPN) is a 145 kDa sarcomeric protein specifi-
cally expressed in striated muscle.1 MYPN contains five im-
munoglobulin (Ig) domains and is structurally similar to the
ubiquitously expressed actin-associated protein palladin
(PALLD), after which it is named.1,2 As opposed to MYPN,
PALLD is expressed in various isoforms and in particular its
longest 200 kDa isoform, containing five Ig domains, is highly
homologous to MYPN and predominantly expressed in stri-
ated muscle.3 Within the Z-line of skeletal muscle, both
MYPN and PALLD bind to α-actinin and nebulin1 as well as
PDZ-LIM proteins, including Cypher/ZASP, CLP36, ALP, and
RIL.4 In addition, MYPN is present in the nucleus and the
I-band, where it binds to the stress-inducible protein cardiac
ankyrin repeat protein (CARP/Ankrd1), which is associated
with the titin N2A region in the I-band and shuttles to the
nucleus, where it functions as a transcriptional cofactor, nega-
tively regulating muscle gene expression.1,5
Heterozygous dominant negative MYPN gene mutations
are associated with human hypertrophic, dilated, and restric-
tive cardiomyopathy (RCM).6–9 Furthermore, homozygous
loss-of-function MYPN truncating mutations (nonsense,
frameshift, or splice-site mutations), resulting in reduced
MYPN expression, were recently identified in patients with
slowly progressive cap myopathy,10 a relatively mild form of
slowly progressive nemaline myopathy (NM) with or without
intranuclear rods,11 and mildly progressive congenital myopa-
thy with hanging big toe.12 This demonstrates the importance
of MYPN in striated muscle, although its function has
remained elusive.
To provide insights into the role of MYPN in skeletal muscle,
we generated and studied MYPN knockout (MKO) mice. MKO
mice show no signs of muscular dystrophy but have reduced
myofibre cross-sectional area (CSA), resulting in decreased iso-
metric force and power output. Furthermore, MKO mice ex-
hibit progressive Z-line widening and show increased injury
after downhill running. In the present study, we demonstrate
that MYPN promotes skeletal muscle growth through activa-
tion of the serum response factor (SRF) signalling pathway.
Methods
Generation of constitutive myopalladin knockout
mice
Mypn genomic DNA was isolated from a 129SVJ mouse geno-
mic library (Stratagene, La Jolla, CA) and used to generate a
MYPN-targeting construct for the fusion of the endogenous
Mypn promoter with LacZ, resulting in knockout of MYPN
(Supporting Information, Figure S1A). The construct was cre-
ated in the pBluescript II KS+ vector (Addgene), and the 5′
arm of homology consisted of a 4091 bp BamHI-SalI fragment
upstream of the MYPN start codon in exon 2 followed by a
LacZ-neomycin cassette. The 3′ arm of homology was a 4351
SalI-NotI fragment downstream of the Mypn start codon.
The targeting construct was verified by sequencing
and linearized with NotI before electroporation into R1 ES
cells at the Transgenic Core Facility at the University of
California, San Diego, CA, USA. G418-resistant ES clones were
screened for homologous recombination by MfeI digestion of
ES cell DNA and Southern blot analysis with a 422 bp probe
generated by PCR on mouse genomic DNA with Mypn specific
primers (sense: GGAAGGCTGTAGAGCTATAAGGCATTCTAG; re-
verse: GCTTCAACCTTGCTATCATAGTTAAGGATG) (Supporting
Information, Figure S1B). The wild-type (WT) allele is repre-
sented by the band of 8041 kb, whereas the 9336 kb band
represents the correctly targeted mutant allele. Cells from
two independent homologous recombinant ES clones were
microinjected into C57BL/6 blastocysts and transferred into
pseudopregnant mice. Male chimeras resulting from the
microinjections were bred with female Black Swiss mice
to generate germ line transmitted heterozygous MKO mice,
which were subsequently intercrossed to generate homozy-
gous MKO mice. Offspring from intercrosses were geno-
typed by PCR on mouse tail DNA using WT (sense:
GTTCGGTATTCTCCTCGTTTTG; reverse: CTCTGGCGGGCTG-
TCTTTAGG) and mutant allele-specific primers (sense:
GTTCGGTATTCTCCTCGTTTTG; reverse: AGATGAAACGCCG-
AGTTAACGC). Successful ablation of the Mypn gene was
confirmed by northern blot analysis using a 1000 bp probe
(sense: GGCCGCAGTACAGTTCTGAAACCCAGTCCA; reverse:
TCTCTGTACCACTCGACTTTCGGAGATGGG) (Supporting Infor-
mation, Figure S1C). Furthermore, western blot analysis
using a custom-made polyclonal antibody against MYPN13
(1:1000; see also Supporting Information, Table S2) con-
firmed the absence of MYPN from heart and skeletal
muscle (Supporting Information, Figure S1D). The mice were
backcrossed for 10 generations into the C57BL/6J back-
ground. All animal studies were approved by the University
of California San Diego Animal Care and Use Committee
and the Italian Ministry of Health. Animal procedures were
performed in full compliance with the guidelines for the
Guide for the Care and Use of Laboratory Animals, eighth
edition (2011) published by the US National Institutes of
Health and the Directive 2010/63/EU of the European
Parliament on the protection of animals use for scientific
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purposes. Mice for experiments were sacrificed by cervical
dislocation following anaesthetization by intraperitoneal
(IP) injection of a mixture of ketamine (100 mg/kg) and
xylazine (5 mg/kg).
Mouse surgical procedures
For surgical procedures, mice were anaesthetized by IP injec-
tion of a mixture of ketamine (100 mg/kg) and xylazine (5
mg/kg) and the depth of anaesthesia was monitored by toe
pinch. To study muscle regeneration following degeneration,
100 μL of 1.2% BaCl2 in 0.9% saline solution was injected into
the right tibialis anterior (TA) muscle of 10-week-old male
mice under general anaesthesia, while 0.9% saline solution
was injected into the contralateral leg. The hindlegs were
shaved before injection, allowing for better visualization of
the TA. At 4, 7, 14, 21, and 28 days after injection, mice were
sacrificed and TA muscles were excised and frozen in
isopentane cooled with liquid nitrogen. For denervation, 10-
week-old male mice were anaesthetized and the sciatic nerve
of the left limb was cut, while the right limb served as control.
Mice were sacrificed 21 days after denervation and muscles
were frozen in cooled isopentane.
Histology, immunofluorescence, and transmission
electron microscopy
Transverse cryosections of 10 μm thickness of mouse hind
limb muscles [TA, extensor digitorum longus (EDL), soleus]
were subjected to haematoxylin and eosin, and Picro Sirius
Red staining. Fibre-type distribution in TA, EDL, and soleus
muscle was determined by measuring myosin heavy chain
(MHC) isoform levels by SDS-PAGE as previously described.14
To measure CSA of myofibres of different fibre type, trans-
verse cryosections were stained with antibodies against lami-
nin and myosin isoform specific antibodies (Supporting
Information, Table S2). Briefly, cross sections were incubated
with primary antibodies diluted in phosphate buffered saline
(PBS) for 3 days at 4°C, and subsequently with secondary an-
tibodies for 3 h at room temperature (RT) (Supporting Infor-
mation, Table S2). The long incubation time was necessary
because the myosin isoform specific antibodies gave only a
weak signal. Imaging was performed on a Leica DM IL
inverted fluorescent microscope at ×10 magnification and im-
age analyses were performed using ImageJ (National Insti-
tutes of Health). Fibre numbers were counted in mid-belly
muscle cross sections of TA, EDL, and soleus muscle.
For confocal microscopy, TA muscles were stretched,
cryosectioned, and stained as previously described.15 The pri-
mary and secondary antibodies used are listed in Supporting
Information, Table S2. Because the MYPN antibody13 was
not working well for immunofluorescence staining, MYPN
localization was determined by electroporation of TA muscle
with PmCherry-N1-MYPN. A NEPA21 Electroporator
(SonidelTM Limited) with a CUY560-5-0.5 probe was used ac-
cording to the manufacturer’s instructions. Confocal micros-
copy was performed on a Leica SP8 inverted confocal
microscope with a ×60 oil immersion lens. Individual images
(1024 × 1024) were converted to tiff format and merged as
pseudocolour RGB images using ImageJ.
Transmission electron microscopy (TEM) was performed on
EDL and soleus muscles as previously described.13 Z-line
density profiles were obtained using the plot profile function
in ImageJ based on the analysis of >100 Z-lines per muscle
from 2–3 mice per genotype and time point and Z-line width
was measured at the base of the plots.
Muscle mechanical analyses
Experiments on whole muscle
Force–velocity relation (Florence lab) For mechanical studies,
EDL and soleus muscles were dissected under a stereomicro-
scope and mounted horizontally between the lever of a
motor/force transducer system (305C, Aurora Scientific Inc.)
and a lever carried by a micromanipulator in a trough, contain-
ing physiological Krebs–Henseleit solution (119 mM NaCl, 4.7
mM KCl, 1.0 mM MgSO4, 25 mM NaHCO3, 1.2 mM KH2PO4,
and 1.1 mM glucose), continuously saturated with carbogen
(95% O2 and 5% CO2, pH 7.4) at RT (23–25°C). The muscle
was straightened just above its slack length using the micro-
manipulator. The trough was sealed with a Perspex cover
and mounted vertically on the stage with the motor/force
transducer system on the top. Trains of stimuli of alternate po-
larity to elicit fused tetani (frequency 100–120 Hz for EDL mus-
cle and 50–60 Hz for soleus muscle) were delivered by means
of two platinum wire electrodes running parallel to the mus-
cle, 1 cm apart. The intensity of the stimuli was increased until
the isometric plateau force reached a maximum constant
value, T0 (indicating that all cells in the muscle were activated).
Muscle length was further finely adjusted using the microma-
nipulator to obtain the maximum isometric force correspond-
ing to the plateau of the force–length relation. Isometric force
was normalized to muscle wet weight (w) and CSA, calculated
according to the relation: CSA = (w · cosθ) / (Lf · δ) (cm
2), where
θ is the pennation angle of the fibres (8.3° for EDL muscle and
8.7° for soleus muscle, table 1 in Ref. 16), Lf is the fibre length
(cm), and δ is the muscle density (1.056 g/cm3)17. Lf was ob-
tained by multiplying the muscle length by 0.51 in EDL muscle
and 0.75 in soleus muscle (table 1 in Ref. 16). The force–
velocity relation was determined by measuring the velocity
of steady shortening (V) after a drop in force from T0 to a pre-
set value T < T0 (see Supporting Information, Figure S3A for
the protocol). The force–velocity points were fitted to the Hill
hyperbolic equation17: (T + a) · (V + b) = (V0 + b) · a, where a, b,
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and V0 (unloaded shortening velocity) are the regression
parameters.
Eccentric contraction-induced injury (Chicago lab) The effect
of repetitive eccentric contractions of EDL muscle was tested
essentially as previously described.13 Briefly, the fifth toe EDL
muscle was dissected in Ringer’s solution (137 mM NaCl, 5
mM KCl, 24 mM NaH2PO4, 2 mM CaCl2, 1 mM MgSO4, 11
mM glucose, and 1 mg/L curare) and secured in a muscle-
testing chamber, after which muscle length was adjusted by
laser diffraction to a sarcomere length of ~3.0 μm. Briefly,
passive tension was measured three times at 2 min intervals
by imposing a 15% Lf stretch at a rate of 2 Lf. Subsequently,
maximum isometric force was measured three times at 5
min intervals by applying a 400 ms train of 0.3 ms pulses de-
livered at 100 Hz, while maintaining constant muscle length.
Next, each muscle underwent a series of 10 eccentric contrac-
tions in which the muscle was first maximally activated
isometrically until tension stabilized (~200 ms) and then
stretched 15% Lf at a rate of 2 Lf. At the end of the protocol,
isometric force was again measured three times. Isometric
force was normalized to the calculated CSA as mentioned
earlier.
Experiments on skinned fibres
Active mechanics on single muscle fibres (Florence lab) To in-
vestigate the effect of MYPN ablation on force per myosin
motor and calcium sensitivity of the contractile apparatus, ex-
periments were performed on glycerinated skinned fibre seg-
ments from EDL and soleus muscle essentially as described
previously.18,19 The composition of skinning, relaxing, rigour,
pre-activating, and activating solutions has been reported
previously (Ref. 19 and references therein). Dissected muscles
were placed in skinning solution overnight at 4°C and subse-
quently stored in storage solution at 20°C for up to 3–4
weeks. For mechanical testing, a muscle was transferred to
a Petri dish with the bottom covered by Sylgard (Dow
Corning Ltd), filled with storage solution, and kept at 4–6°C.
A 2- to 4-mm-long fibre segment was cut and T-shaped alumi-
num clips were mounted at its extremities for attachment to
the transducer hooks. The fibre was mounted in a drop of
relaxing solution between the lever arms of a loudspeaker
motor and a capacitance force transducer and, to minimize
the shortening of the fibre segment by extension of the dam-
aged extremities and the development of inhomogeneity in
sarcomere length across the fibre, the two ends of the fibre
were fixed with glutaraldehyde in rigour solution (5%
vol/vol) and glued to the clips with shellac dissolved in etha-
nol.19,20 Average sarcomere length (sl), width (d), and height
(h) of the fibre were measured in 2 to 3 points along the fibre
with a ×40 dry objective (NA 0.60; Carl Zeiss MicroImaging
Inc.) and a ×25 eyepiece. The sl of both MKO and WT fibres
was set to 2.4–2.6 μm. The CSA of the fibre was determined
assuming elliptical geometry (CSA = π/4·d·h), where d is the
width and h is the height of the fibre.
Using a rapid solution-exchange system, a fibre was trans-
ferred from relaxing solution to pre-activating solution at 2°
C, and after 3 min to activating solution at low temperature,
where the isometric force developed is 0.1–0.2 the isometric
force developed at the test temperature (12–13°C). The fibre
was then transferred to activating solution at the test temper-
ature for 6–8 s and subsequently to relaxing solution at the
same temperature. This protocol prevents the development
of most of the force during diffusion of Ca2+ and thus mini-
mizes the development of sarcomere non-uniformities. The
solution exchange system allowed continuous recording of
length changes of a selected population of sarcomeres
(500–1200) by a striation follower (Ref. 19 and references
therein). Baseline force in the activating solution at the test
temperature was determined by superimposing on the iso-
metric contraction a fast shortening (rise time: 3 ms, ampli-
tude: 10% of the initial bundle length L0) that induces slack
in the fibre. The half-sarcomere strain–isometric force rela-
tion (Y0–T0) was obtained by determining fibre stiffness at dif-
ferent [Ca2+] (pCa range, 6.5–4.5) by imposing step changes
(range 3 to +3 nm per half-sarcomere) on an isometrically
contracting fibre. Half-sarcomere stiffness was estimated as
the slope of the relation between the force attained at the
end of the steps and the size of the step as measured at
the level of the half-sarcomere (T1 relation, Supporting Infor-
mation, Figure S3B). The half-sarcomere strain (Y0) was deter-
mined as the intercept of the linear regression to the T1
points with the abscissa.
To determine the force–pCa relation, isometric force (T0)
at any [Ca2+] was normalized to T0 at saturating [Ca
2+]
(T0,4.5). The relation was fitted with the sigmoid Hill equa-
tion,21 allowing for calculation of the Hill coefficient (nH), indi-
cating the steepness of the relation and thus the
cooperativity in the Ca2+ activation process, and pK = pCa at
T0 = 0.5·T0,4.5, a measure of the Ca
2+ sensitivity of the con-
tractile material.
Passive mechanics on single muscle fibres (Chicago lab) Pas-
sive mechanical properties of single muscle fibres from TA
and soleus muscle were determined as previously de-
scribed.14 Briefly, TA and soleus muscles were dissected and
placed in relaxing solution [59.4 mM imidazole, 86 mM
KCH4O3S, 0.13 mM Ca (KCH4O3S)2, 10.8 mM Mg (KCH4O3S)2,
5.5 mM K3EDTA, 1 mM KH2PO4, 5.1 mM Na2ATP, and 50
μM leupeptin] for at least 60 min after which single fibre seg-
ments were dissected and kept in storage solution [170mM K
propionate, 5 mM K3EGTA, 5.3 mM MgCl2, 10 mM imidazole,
21.2 mM Na2ATP, 1 mM NaN3, 2.5 mM glutathione, 50 μM
leupeptin, and 50% (vol/vol) glycerol] at 20°C for up to 3
weeks. All chemicals were obtained from Sigma-Aldrich. For
mechanical testing, fibre bundles were placed in relaxing solu-
tion and single fibre segments (2–3 mm in length) were
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carefully dissected and transferred to a mechanical testing
chamber, filled with relaxing solution, in which they were tied
to a force transducer and a motor. Sarcomere length was
measured by transilluminating the fibre with a laser and
projecting the diffraction pattern onto a photodiode array
above the fibre. Muscle fibres were stretched to failure in
250 μm increments at 2 min intervals by the use of a microm-
eter attached to the motor. Sarcomere length and passive
tension were recorded at the end of each 2 min interval,
and the Young’s modulus of the resulting stress–strain curve
was calculated as the tangent at a sarcomere length of 3.0
μm. Hierarchical models were used for analysis of single
fibres to allow inclusion of within muscle and between muscle
variability.22
Data recording and analysis In both labs, force and length sig-
nals were recorded with a multifunction I/O board (PCI-6110,
National Instruments, Austin, TX, USA), and a dedicated pro-
gramme written in LabVIEW (National Instruments) was used
for signal recording and analysis. Sample rate: 10 μs/point or
0.5 ms/point.
Treadmill running
To test the exercise capacity of MKO mice, 3-month-old male
mice were subjected to exercise endurance tests on a five-
lane treadmill for mice (2Biological Instruments) equipped
with an electric grid carrying a mild electric current forcing
the animals to run. Following 1 day of acclimatization (0% in-
clination for 10 min at 15 cm/s), mice were subjected to an
uphill running test at 15% inclination. One week later, mice
were subjected to a downhill running test at 15% declination
for four consecutive days. For both uphill and downhill run-
ning tests, mice were warmed up for 10 min at 18 cm/s,
whereafter the speed was increased by 3 cm/s every 2 min
until exhaustion. The time and speed at which the mouse
could not maintain sufficient speed to remain off the shock
grid was recorded. Mice were sacrificed at various time
points after the last downhill run and gastrocnemius and so-
leus muscles were processed for histological and TEM analy-
ses. After the last run, some mice were injected with 100 μL
1% Evans blue dye in PBS at a 1% volume relative to body
mass (200 μL per 20 g mouse), whereafter muscles were dis-
sected out 24 h later and snap frozen in isopentane cooled
with liquid nitrogen. Cryosections (10 μm) were fixed in cold
acetone (20°C) for 2 min, mounted with ProlongTM Gold
Antifade Mountant (Thermo Fisher Scientific), and visualized
with the Olympus Fluoview FV1000 laser scanning confocal
microscope (Olympus) at the excitation wavelength of
568 nm.
Plasmid constructs
The plasmid constructs pXJ40-FLAG-human MRTF-A23 and
pGADT7-human MRTF-B24 were kindly provided by Dr. Carol
Otey (University of North Carolina, Chapel Hill, NC, USA),
while the 2FLAG-mouse MRTF-A construct was provided by
Dr. Maria Vartiainen (University of Helsinki, Finland). MYPN
and MRTF-A cDNAs were isolated by PCR using available con-
structs or mouse/human cDNA as a template and cloned into
pXJ40-HA, pGADT7-AD, pGBKT7-BD, PmCherry-N1, pTBSG,
and/or pTBMalE325 vectors using digestion cloning, Ligation
Independent Cloning, or the In-Fusion HD cloning kit
(Clontech Laboratories) according to the manufacturer’s in-
structions. Primer sequences are listed in Supporting Infor-
mation, Table S1. All constructs were confirmed by
sequencing.
Culturing of cell lines
Human embryonic kidney 293 cells were maintained at sub-
confluence in Dulbecco’s modified Eagle’s medium (DMEM)
containing 4.5 g/L glucose (Sigma-Aldrich) supplemented with
10% heat inactivated fetal bovine serum (FBS) (Sigma-Al-
drich), 2 mM Ultraglutamine (Lonza), 10 U/mL penicillin,
and 100 U/mL streptomycin (Lonza). Cells were grown at
37°C in a humidified atmosphere with 5% CO2. The myogenic
C2C12 mouse cell line was maintained at subconfluence in
DMEM containing 4.5 g/L glucose (Sigma-Aldrich) supple-
mented with 20% heat inactivated FBS, 2 mM Ultraglutamine,
10 U/mL penicillin, and 100 U/mL streptomycin and grown at
37°C in a humidified atmosphere with 5% CO2. C2C12 cells
were differentiated at 95% confluence by reducing serum
levels to 2% horse serum (Thermo Fisher Scientific).
Serum response factor-luciferase reporter assays in
C2C12 cells
C2C12 cells were plated on 12-well dishes coated with 0.1%
gelatin from porcine skin (Sigma-Aldrich) and transiently
transfected using Lipofectamine LTX (Thermo Fisher Scientific)
according to the manufacturer’s instructions, resulting in a
transfection efficiency of approximately 70%. Cells were
cotransfected with pxj40-HA expression plasmids encoding
HA-tagged full-length MYPN or PALLD isoform 4 (25, 50,
and 100 ng) and/or FLAG-tagged MRTF-A (3 ng), as indicated,
a pGL3 basic rat smooth muscle α-actin promoter firefly lucif-
erase reporter plasmid26 (250 ng), and the pRL-TK plasmid
(Promega) expressing Renilla luciferase under the control of
the thymidine kinase promoter to normalize for transfection
efficiency (5 ng). C2C12 myoblasts were induced to differen-
tiate 24 h after transfection and were lysed after 48 h of
differentiation. Firefly and Renilla luciferase activities were
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measured on a SynergyTM H4 Multi-Mode Microplate Reader
(BioTek) using the Luc-Pair Duo-Luciferase Assay Kit 2.0
(GeneCopoeia) according to the manufacturer’s instructions.
Firefly luciferase activity was normalized to Renilla luciferase
activity to account for variations in transfection efficiency.
All experiments were performed in triplicate and repeated
at least three times.
Isolation of primary muscle cells
Primary myoblasts were isolated from the limbs of 3-day-old
neonatal MKO and WT mice using a protocol modified from
Ref. 27. Briefly, skinned mouse limbs were collected from
neonatal pups, minced, and subjected to serial trypsinization
(successive 25 min periods until all tissue was digested) in
0.05% trypsin solution B (Biological Industries, VWR) in PBS
by continuous stirring at 37°C. Cells were collected by centri-
fugation at 1000×g for 5min and resuspended in proliferation
medium [DMEM with 4.5 g/L glucose (Sigma-Aldrich), 20%
heat inactivated FBS (Sigma-Aldrich), 2 mM Ultraglutamine
(Lonza), 10 mM Hepes (Lonza), and 10 U/mL penicillin and
100 U/mL streptomycin (Lonza)]. Following filtration of the
homogenate in sequence through 100, 70, and 40 μm nylon
mesh cell strainers, cells were preplated for 15min on a tissue
culture dish coated with 0.1% porcine skin gelatin (Sigma-Al-
drich), and subsequently for 1 h on an uncoated dish to
remove fibroblasts. To further enrich the myoblast popula-
tion, unwanted cells were removed using Feeder Removal
Micro-Beads (Miltenyi Biotec), and subsequently the Satellite
Cell Isolation Kit (Miltenyi Biotec) using LS separation
columns and a gentleMACS dissociator (Miltenyi Biotec) fol-
lowing the manufacturer’s instructions. Cells were plated on
a gelatin-coated plate in proliferation medium supplemented
with 10 ng/mL human basic fibroblast growth factor (Twin He-
lix) and 25 μM forskolin (Sigma-Aldrich) to prevent spontane-
ous differentiation. After 24 h, cells were washed in PBS, and
every 48 h, they were split by gentle detachment of myo-
blasts using 0.5 mM EDTA in PBS followed by half an hour
preplating for removal of the few remaining fibroblasts. For
experiments, the highly purified myoblasts were plated on
gelatin-coated six-well plates (1.2 × 106 cells/well) in prolifer-
ation medium containing 10 ng/mL basic fibroblast growth
factor and induced to differentiate at 80% confluence by ad-
dition of differentiation medium [DMEM with 4.5 g/L glucose
(Sigma-Aldrich), 2% horse serum (Thermo Fisher Scientific), 2
mM Ultraglutamine (Lonza), 10 mM Hepes (Lonza), and 10
U/mL penicillin and 100 U/mL streptomycin (Lonza)].
Experiments on primary muscle cells
To study proliferation rate of MKO and WT skeletal muscle
primary cells, the Click-iTTM EdU Alexa Fluor 488 imaging kit
(Thermo Fisher Scientific) was used. Briefly, MKO and WT
skeletal muscle primary cells were plated on gelatin-coated
coverslips the day before treatment with 10 μM EdU for
2 h. Subsequently, cells were washed with PBS, fixed with
4% paraformaldehyde in PBS for 10 min, washed twice with
3% bovine serum albumin (BSA) (Bio-Rad) in PBS, and perme-
abilized with 0.5% Triton X-100 in PBS for 30 min at RT. After
two washes with 3% BSA in PBS, cells were incubated with the
Click-iT® reaction cocktail for 30 min at RT, protected from
light. Cells were then washed again with 3% BSA in PBS and
incubated with Hoechst 33342 solution (5 μg/mL) for 30
min at RT. Imaging was performed on a Leica DM IL
inverted fluorescent microscope at ×10 magnification and im-
age analyses was performed using ImageJ. The number of
EdU positive nuclei as a percentage of the total number of
Hoechst-stained nuclei counted in 10 fields was calculated.
All experiments were performed in triplicate and repeated
at least three times.
For immunofluorescence staining, cells were either un-
treated or infected with adenovirus expressing SRFVP16
[AdSRFVP16; 36 infectious units (ifu)]28,29 or β-galactosidase
(AdLacZ; 10 ifu) added to the differentiation medium, after
which cells were collected 40 h later. Cells were fixed with
4% paraformaldehyde for 5 min and subsequently processed
for immunofluorescence staining directly in the well using a
pap pen. Cells were incubated for 1 h with
permeabilization/blocking solution containing 3% goat serum
and 0.1% Triton X-100 in PBS and subsequently incubated
with antibodies against α-actinin or desmin diluted in
permeabilization/blocking solution overnight at 4°C (see
Supporting Information, Table S2 for details). Following wash-
ing in 0.1% Triton X-100 in PBS, sections were incubated with
secondary antibodies for 1 h at RT. After washing, slides were
incubated for 5 min with 300 nM 4′,6-diamidino-2-
phenylindole (DAPI; Sigma-Aldrich) and subsequently
mounted with ProlongTM Gold Antifade Mountant (Thermo
Fisher Scientific). Light imaging was performed on an EVOSTM
XL Imaging System (Thermo Fisher Scientific), while fluores-
cent imaging was performed on an Olympus CellR time
laps microscope at ×10 magnification. Composite images
were generated and the fusion index was determined as
the number of nuclei within α-actinin-stained myotubes
containing three or more nuclei as a percentage of the total
number of DAPI-stained nuclei in the same field. Myotube
width of arbitrarily selected myotubes was measured using
ImageJ.
For determination of protein synthesis, cells differentiated
for 24 h were incubated with 1 μM puromycin
dihydrochloride (Merck Millipore) for 30 min and subse-
quently subjected to western blot analysis using an antibody
against puromycin (Supporting Information, Table S2).30 For
determination of protein degradation, cells were treated with
1 μM MG262 (CliniSciences) in differentiation medium for 24
h, after which cells were collected and subjected to western
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blot analysis using an antibody against ubiquitinated proteins
(Supporting Information, Table S2).
An SRF reporter assay was performed by coinfection of
cells with adenovirus expressing SRF-RE reporter-based firefly
luciferase (AdSRF-RE luc; 40 ifu) or β-galactosidase (AdLacZ;
10 ifu) control as well as Renilla luciferase (AdRen-Luc; 10
ifu) for normalization.31 The virus was added to the differen-
tiation medium containing 5% horse serum, and cells were
harvested 40 h later. Firefly luciferase and Renilla luciferase
activities were determined using the Luc-Pair Duo-Luciferase
Assay Kit 2.0 (GeneCopoeia) as described earlier. Firefly lucif-
erase activity was normalized to Renilla luciferase activity to
account for variations in transfection efficiency. All experi-
ments were performed in triplicate and repeated at least
three times.
Co-immunoprecipitation
Human embryonic kidney 293 cells were plated on 60 mm
dishes and transfected with pXJ40-HA-MYPN FL and/or
pXJ40-FLAG-MRTF-A using Lipofectamine LTX (Thermo Fisher
Scientific); 48 h after transfection, cells were harvested and
resuspended in 200 μL of IP buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100)
supplemented with protease inhibitors (1 mM
phenylmethylsulfonyl fluoride and Complete Protease Inhibi-
tor Cocktail Tablets; Roche). After 20 min incubation on ice,
the lysate was centrifuged at 14 000×g for 10 min at 4°C
and 15% of the supernatant was added with 4× SDS protein
sample buffer [100 mM Tris-HCl pH 6.8, 40% (v/v) glycerol,
312 mM sodium dodecyl sulfate (SDS), 174 mM dithiothreitol
(DTT), 0.04% (w/v) bromophenol blue] and submitted to
western blot analysis with FLAG-antibody, whereas the re-
maining supernatant was immunoprecipitated with 10 μg
HA-antibody overnight at 4°C with agitation (see Supporting
Information, Table S2 for antibodies); 30 μL of Protein G
Dynabeads (Novex, Thermo Fisher Scientific) were used per
IP. After washing in IP buffer supplemented with protease in-
hibitors, the beads were mixed with lysate and first incubated
for 5–10 min at RT, and subsequently for 1 h at 4°C with agi-
tation. At the end of the incubation, the mixed beads-lysate
was washed five times with IP buffer and added with 4×
SDS protein sample buffer for western blot analysis using
FLAG-antibody.
RNA extraction and quantitative real-time PCR
Total RNA was isolated and reverse transcribed as previously
described,32 whereafter quantitative real-time PCR (qRT-
PCR) was performed in triplicate with custom designed oligos
(Supporting Information, Table SI) using the GoTaq qPCR
Master Mix (Promega). A ViiATM 7 Real-Time PCR System
(Applied Biosystems) was used with the following thermal cy-
cler conditions: 95°C for 10 min, followed by 40 cycles of 95°C
for 15 s, and 60°C for 1 min. Gapdh was used for normaliza-
tion and relative expression analysis was performed using
the Ct method.
RNA-sequencing and analysis
DNase I-treated RNA was analysed on a Bioanalyzer 2100 in-
strument (Agilent), and only RNA samples with an RNA integ-
rity number ≥ 8 were used for the analyses. Indexed
sequencing libraries were generated from 1 μg RNA using
the TruSeq Stranded Total RNA Sample Prep Kit with Ribo-
Zero Gold ribosomal RNA reduction chemistry (Illumina). Elec-
trophoresis of the libraries on a Bioanalyzer 2100 instrument
showed highest peaks at 230–270 bp. Paired-end multiplexed
sequencing of libraries (four per flow cell lane) to generate
reads of 100 bp was performed on a HiSeq 1000 instrument
with TruSeq SBS and PE Cluster v3 Kits (Illumina); 70–100 mil-
lion reads per sample were obtained. STAR v2.533 was used to
align each sample’s paired-end reads to the UCSC Mus
musculus reference genome (build GRCm38/mm10). The
raw read counts were normalized with TMM implemented
in the Bioconductor package ‘edgeR’34 and differential ex-
pression analysis of read counts was performed using
glmQLFit and glmQLFTest functions. For analyses of RNA-
sequencing (RNA-Seq) data, P values were corrected for mul-
tiplicity according to the Benjamini–Hochberg procedure
(false discovery rate).35 The threshold used was false discov-
ery rate ≤ 0.1 and log2 count per million ≥ 0. Hierarchical clus-
tering was performed using Cluster 3.0 software,36 including
the significantly modulated genes. Clustering was performed
using the Pearson correlation function. The heatmap images
were exported using Java TreeView software.36 For gene on-
tology (GO) analysis, the ontology database within Enrichr37
was used to find significant enriched GO terms (P ≤ 0.01).
The commercial Ingenuity Pathway Analysis (www.qiagen.
com/ingenuity) software (Qiagen) was used to determine sig-
nificantly affected pathways and molecular networks. Raw
data files for the RNA sequencing analysis have been depos-
ited in the NCBI Gene Expression Omnibus under accession
number GEO: GSE124763.
Serum response factor target gene analysis
Serum response factor target genes were identified using the
‘ENCODE Transcription Factor Targets’ reported in the
Harmonizome database (http://amp.pharm.mssm.edu/
Harmonizome/). The SRF target gene set was subsequently
reduced through overlap with the significant ChIP-Seq SRF
peaks in the C2C12 cell line [downloaded from the NCBI
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GEO databank (GEO: GSE36024)] that fell inside promoter re-
gions, using the intersectBed command of BEDTools suite.38
SDS-PAGE and western blot analysis
Fibre-type distribution in TA, EDL, and soleus muscle was de-
termined by measuring MHC isoform levels as previously de-
scribed.14 For western blot analysis, muscle tissue was
homogenized in RIPA buffer containing 50 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.5 mM DTT, 1 mM EDTA, 1% (v/v) SDS,
1% (v/v) Triton X-100, protease inhibitors (1 mM
phenylmethylsulfonyl fluoride and Complete Protease Inhibi-
tor Cocktail Tablets; Roche), and phosphatase inhibitors
(PierceTM Phosphatase Inhibitor Mini Tablets; Thermo Fisher
Scientific) using a TissueLyser II (Qiagen). Cells were lysed in
standard RIPA buffer containing 0.1% SDS. Protein concentra-
tion was determined using the Bio-Rad DCTM Protein Assay Kit
(Bio-Rad) according to the manufacturer’s instructions.
Western blot analysis was performed using the primary and
secondary antibodies listed in Supporting Information, Table
S2. The ImmobilonTM Western Chemiluminescent HRP Sub-
strate (Merck Millipore) was used and chemiluminescence
was detected on a ChemidocTM MP System (Bio-Rad). Relative
protein expression was determined by densitometry using
ImageJ.
Protein expression and purification
The coding sequence of the MYPN Ig3 domain was
subcloned into the pTBSG vector containing an N-terminal
His6-tag and a tobacco etch virus (TEV) protease cleavage
site. The coding sequences of the MYPN Ig4 and Ig3–4 do-
mains were subcloned into the pTBMalE3 vector containing
an N-terminal MBP-tag, followed by a His-tag and a TEV
protease cleavage site.25 The plasmids were transformed
into BL21(DE3) cells (New England Biolabs) and proteins
were expressed using auto-induction media,39 starting the
growth at 37°C until A600 = 0.6–0.8 after which the temper-
ature was reduced to 18°C for 20–24 h. Cells were har-
vested by centrifugation for 20 min at 2000×g,
resuspended in lysis buffer (50 mM Tris-Cl, 300 mM NaCl,
10 mM imidazole, pH 7.4, and Complete Protease Inhibitor
Cocktail Tablets; Roche), and lysed by sonication for 20
min. After centrifugation of the lysate at 48 000×g for 45
min to pellet cell debris, the supernatant was loaded onto
a pre-equilibrated Proteindex™ HiBond™ Ni-NTA column
(Marvelgent Biosciences). The column was washed twice
with 50 mL wash buffer (50 mM Tris-Cl, 300 mM NaCl, 25
mM imidazole, pH 7.4), whereafter the fusion protein was
eluted with 50 mL elution buffer (50 mM Tris-Cl, 300 mM
NaCl, 250 mM imidazole, pH 7.4) at RT. The N-terminal
His6-tag was cleaved overnight at 18°C in elution buffer
using TEV protease. MYPN Ig4 and Ig3-4 proteins expressed
from the pTBMalE3 vector were further purified by loading
onto a 5 mL pre-packed MBPTrap™ column (GE Healthcare
Life Sciences), followed by cation exchange chromatography
at pH 5.5 as previously described.40 Protein purity was con-
firmed by SDS-PAGE and the purified protein was dialysed
into storage buffer (20 mM Hepes, 150 mM NaCl, 2 mM
DTT, pH 7.5).
Actin co-sedimentation assays
Actin was purified from rabbit muscle acetone powder (Pel-
Freez Biologicals) and snap frozen as previously described.41
Frozen stocks of G-actin were allowed to thaw on ice and af-
ter removal of insoluble protein by centrifugation at 15 000×g
in a Sorvall™ microcentrifuge, actin was polymerized by addi-
tion of an equal volume of 2X F-buffer (20 mM Tris, 200
mM KCl, 4 mM MgCl2, 4 mM DTT, pH 8.0) and incubation
for 60 min at RT. Purified MYPN domain was centrifuged at
15 000×g for 30 min to pellet any insoluble protein before
use. For F-actin binding assays, various concentrations (1–30
μM) of polymerized actin were incubated with 10 μM MYPN
Ig3, Ig4, or Ig3–4 domains for 1 h in a final volume of 100
μL and subsequently centrifuged at 150 000×g for 30 min in
a Beckman Airfuge® Air-Driven ultracentrifuge. Pellets were
resuspended in 100 μL 2x SDS running buffer and 35 μL of
4x loading dye was added to both supernatants and pellets.
SDS-PAGE was performed on 15% gels and gel bands were vi-
sualized by Coomassie staining. The relative amount of MYPN
in supernatants and pellets was measured by densitometry
using ImageJ. Actin bundling and crosslinking was monitored
as before with the modification that the centrifugation was
first carried out at 5000×g for 10 min to pellet bundled actin
and subsequently at 150 000×g for 30 min to pellet polymer-
ized actin, after which supernatant and pellet fractions (low
speed and high speed) were separated by SDS-PAGE as
before.
Fluorescence microscopy of actin filament bundles
Oregon Green 488 iodoacetamide (Thermo Fisher Scientific)-
labelled G-actin was prepared as previously described.42 5
μM actin was polymerized in F-imaging buffer (5 mM Tris-
HCl, pH 8, 100 mM KCl, 2 mM MgCl2, 0.2 mM DTT, 0.2 mM
ATP, 0.040 mg/mL catalase, and 0.2 mg/mL glucose oxidase)
for 50 min, after which MYPN Ig3 domain (5–20 μM) was
added and further incubated for 50 min before mounting on
a microscope. All images were collected on a Leica TCS SP5
(Leica Microsystems) confocal microscope with a ×63 oil
immersion lens objective.
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Pyrene fluorescence assay
A pyrene fluorescence assay was used to measure the actin
polymerization rate in the presence of MYPN domains.43
Gel-filtered G-actin was labelled with N-(1-pyrene)
iodoacetamide (Molecular Probes) as previously reported.43
Pyrenyl-actin was mixed with unlabelled G-actin to make a
10 μM, 5% pyrene-labelled G-actin stock. In one reaction
tube, 10 μM pyrene-labelled G-actin was incubated with 10
μL of 10x priming solution (10 mM EGTA, 1 mM MgCl2) for
2min in a total volume of 100 μL. In a separate reaction tube,
20 μL of 10x MKEI polymerization buffer (20 mM MgCl2, 250
mM KCl, 10 mM EGTA, 200 mM imidazole, pH 7), 4 μL of 50x
G-buffer without CaCl2 (500mM Tris, pH 8.0, 100mM DTT, 10
mM ATP), and various concentrations of MYPN (0–20 μM)
were mixed in a total volume of 200 μL. The two mixtures
were combined and pyrene fluorescence was immediately
measured on a fluorometre with excitation at 365 nm and
emission at 385 nm until a plateau in fluorescence intensity
was reached. In the G-buffer condition, no KCl was added
while all other steps were identical. Raw data were normal-
ized by subtraction of baseline fluorescence and division by
the steady-state plateau fluorescence. The overall polymeriza-
tion rate of each polymerization curve was determined by
plotting the slope of the linear region of the curve and
converting relative fluorescence units/s into nM actin/s.
Actin filament depolymerization
Pyrene-labelled F-actin (10 μM, 5% pyrene) was prepared by
incubation of pyrene-labelled G-actin in MKEI polymerization
buffer (2 mM MgCl2, 50 mM KCl, 1 mM EGTA, 20 mM imidaz-
ole, pH 7) for 1 h at RT in the dark.44,45 2 μM pyrene-labelled
F-actin was incubated for 30 min with various concentrations
of MYPN Ig3 or Ig3–4 domain (1–20 μM) in a 200 μL reaction
mixture containing 1mM DTT and 0.2mM ATP. Subsequently,
2 μL of 1mM Latrunculin A (Sigma-Aldrich) prepared in DMSO
was added to the mixture and actin filament disassembly was
monitored by detection of pyrene fluorescence for 600 s on a
fluorometer (excitation at 365 nm and emission at 388 nm).
The fluorescence signal was normalized by setting the final
time point intensity of F-actin with Latrunculin A to zero and
the maximum fluorescence for each data set to 1.
Yeast two-hybrid assays
pGBKT-BD bait and pGADT7-AD prey vectors (Clontech Labo-
ratories) containing cDNA encoding the proteins of interest
were cotransformed into the Y2H Gold yeast strain (Clontech
Laboratories) using the Frozen-EZ Yeast Transformation IITM
kit (Zymo Research) following the manufacturer’s instruc-
tions. Transfected cells were spotted on selective plates of
synthetically defined (SD) medium lacking the amino acids
tryptophan (Trp), leucine (Leu), histidine, and adenine con-
taining 120 ng/mL aureobasidin A and incubated at 30°C for
3–4 days to verify interaction. Successful transformation of
the two plasmids was confirmed by growth on SD/-Trp/-Leu
plates. Possible autoactivation of the bait and the prey con-
structs was tested by cotransformation of the bait or prey
vector with empty prey or bait vector, respectively.
Statistical analysis
Data are represented as mean ± standard error of the mean
(SEM) or standard deviation (SD) as indicated. Statistical com-
parisons between MKO and WT were done using the unpaired
Student’s t-test. Simultaneous effects of genotype and an-
other experimental variable were determined using two-way
analysis of variance (ANOVA) with post hoc Fisher’s protected
least-significant difference analysis. P < 0.05 was considered
significant. Statistical analysis was performed using Origin
(OriginLab Corporation) software (muscle mechanics) or Prism
6 software (GraphPad).
Results
Myopalladin knockout mice are smaller compared
with wild-type littermates and have reduced
myofibre cross-sectional area
Constitutive MKO mice were generated by knocking in a LacZ-
Neo cassette downstream of the Mypn promoter, thereby
disrupting the Mypn gene (Supporting Information, Figure
S1). MKO mice were born at Mendelian ratios, were fertile,
and had normal life spans. However, they had significantly
smaller body weight compared with WT littermate control
mice (22% at 3 days, 17% at 4 weeks, and 13% at 8 weeks
of age) (Figure 1A) as well as a similar reduction in TA muscle
weight (20% at 14 days, 16% at 4 weeks, and 13% at 8 weeks
of age; Figure 1B). Histological analyses by haematoxylin and
eosin staining of cryosectioned muscles showed no central-
ized nuclei or necrosis in MKO skeletal muscle up to 1 year
of age (Figure 1C). However, analysis of laminin-stained mus-
cle sections revealed significantly reduced myofibre CSA in
both fast (TA and EDL), and slow (soleus) muscles (~48% in
all three muscles at 8 weeks of age) at all stages (Figure 1D
and data not shown). Quantification of fibre type (1, 2A, 2B,
and 2X) CSA revealed that all fibre types were affected, al-
though there was no significant reduction in the CSA of type
2A and 2X fibres in soleus muscle (Figure 1E–G and
Supporting Information, Figure S2A). The reduction in CSA
of MKO muscle was associated with a significant increase in
fibre number in all three muscles (11% in TA, 38% in EDL,
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and 66% in soleus; Figure 1H). SDS-PAGE of MHC composition
revealed no significant differences in fibre-type distribution
between MKO and WT mice (Figure 1I and 1J). Thus, reduced
muscle weight in MKO mice is due to decreased myofibre CSA
despite an increased myofibre number, suggesting a role of
MYPN in regulating muscle growth.
Figure 1 Baseline muscle characteristics of MKO and WT littermates. (A, B) Body weight (A) and TA weight (B) of MKO and WT mice at different time
points after birth (n = 6–7 per group). (C) Haematoxylin and eosin, and laminin stainings (green) of cross-sectioned EDL muscle from MKO and WT lit-
termate controls of different ages. M, months. (D) Myofibre CSA of TA, EDL, and soleus (SOL) muscle from 8-week-old MKO and WT mice (n = 3 per
group). (E–G) CSA of different fibre types (1, 2A, 2B, and 2X) in TA (E), EDL (F), and SOL (G) muscle (n = 3–5 per group). (H) Total number of fibres in mid-
belly cross sections of TA, EDL, and SOL muscle (n = 3 per group). (I, J) MHC fibre-type distribution in TA (I) and SOL (J) muscle (n = 3 per group). See also
Supporting Information, Figure S2A. (K) TEM of EDL and SOL muscle from MKO and WT mice of different ages showing normal structure, but progres-
sive Z-line widening in MKO EDL muscle from 8months of age. Z-line width is unaltered in SOL muscle (n = 2–3 per group). See Supporting Information,
Figure S2B for low magnification pictures. (L) High magnification micrographs of single sarcomeres from 8-month-old MKO and WT mice showing Z-line
density profiles obtained by averaging the plots of the Z-lines over the areas indicated by yellow boxes. Z-line width was measured at the base of the
plots as shown. (M) Z-line width at different time points in EDL and SOL muscle. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P <
0.001; Student’s t-test.
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Progressive Z-line widening in myopalladin
knockout skeletal muscle
Transmission electron microscopy (TEM) of EDL muscle from
MKO and WT mice at various ages revealed normal sarcomere
organization in MKO muscle, but progressive Z-line widening
beginning at 8months of age (Figure 1K and Supporting Infor-
mation, Figure S2B). No abnormalities inmitochondria or other
organelles were observed, but M-line abnormalities were ob-
served at 2 years of age. Z-line width was increased by 23%,
24%, and 89% in MKO EDL muscle at 8, 12, and 24 months of
age, respectively (Figure 1L and 1M), while there were no dif-
ferences in I-band width (data not shown). In contrast, no in-
crease in Z-line width or other ultrastructural abnormalities
were observed in soleus muscle (Figure 1K and 1M).
Myopalladin ablation affects specific force and
power output in extensor digitorum longus muscle
To investigate the functional consequence of MYPN deletion
on the mechanical properties of skeletal muscle, we measured
isometric force and power output in fast (EDL) and slow (so-
leus) muscle from 10-week-old MKO and WT mice, an age at
which MKO mice have normal Z-line width and well-preserved
sarcomere structure (Figure 1K and 1M). In MKO EDL muscle,
the isometric force (T0) was reduced by 48%, while the esti-
mated CSA was reduced by 21%, resulting in a 38% reduction
in specific isometric force (T0/CSA) (Figure 2E). The force–
velocity relation was determined as shown in Supporting Infor-
mation, Figure S3A. In EDL muscle, the shortening velocity at
each load was significantly reduced in MKO mice compared
with WT mice (Figure 2A), while the curvature of the force–
velocity relation was not significantly altered (Figure 2A, inset
and 2E). Consequently, the power was significantly reduced
in MKO EDL muscle at any load (Figure 2B and 2E). The power
reduction could be ascribed to the reduction in T0 in the ab-
sence of MYPN as relative power was similar in MKO and WT
muscle at the same relative load (Figure 2B, inset). In soleus
muscle, specific isometric force and power were not signifi-
cantly different between genotypes (Figure 2C–E). The reduc-
tion in specific isometric force in MKO EDL muscle may be
related to the method used to estimate the CSA, as it was indi-
rectly measured from the muscle wet weight. To investigate
this, specific isometric force was measured in fully activated
single skinned fibres from EDL and soleus muscles of MKO
andWT mice, where CSA was directly measured in relaxing so-
lution. T0 was significantly reduced by 52% in EDL muscle and
29% in soleus muscle ofMKOmice in respect toWTmice, while
specific isometric force was comparable in both genotypes
(Figure 2J). Thus, the reduced isometric force observed in
EDLMKOmuscle can be fully explained by the reduction in sin-
gle fibre CSA, not accompanied by a proportional reduction in
muscle wet weight.
Myopalladin does not affect the force per myosin
motor and calcium sensitivity
To investigate whether MYPN ablation affects the number
of actin-myosin motors and/or the force per myosin motor,
we estimated the average strain in the myosin motors by
determining the half-sarcomere strain–force relation (Y0–
T0) at different [Ca
2+] in single skinned fibres. Both the
slope and the ordinate intercept of the Y0–T0 relation were
similar in MKO and WT fibres both from EDL (Figure 2F and
2J) and soleus muscle (Figure 2H and 2J), indicating that the
absence of MYPN does not affect the compliance of actin
and myosin filaments, nor the average strain and thus the
average force per attached motor. The effect of MYPN on
the Ca2+ sensitivity of the contractile system was tested
by determining the force–pCa relation. The relations ob-
tained from MKO and WT fibres both of EDL (Figure 2G)
and soleus (Figure 2I) muscles essentially superimpose.
Thus, neither cooperativity in the Ca2+ activation process
nor Ca2+ myofilament sensitivity is affected by the absence
of MYPN (Figure 2J). To determine whether MYPN affects
passive mechanical properties of muscle, passive mechanical
testing was performed. Young’s modulus, as determined
from the slope of the stress–strain curve, was not signifi-
cantly different between genotypes neither in TA or soleus
muscle (Figure 2K). However, while resting sarcomere
length was similar in MKO and WT muscle, MKO fibres from
TA muscle failed at a shorter sarcomere length and lower
stretch, suggesting decreased structural integrity of the fi-
bre lattice (Figure 2K).
Myopalladin knockout mice are more susceptible to
exercise-induced injury
To determine the exercise capacity of MKO mice, endurance
tests were performed on a treadmill. No differences between
genotypes were observed by uphill and downhill running on
the first day of running (Figure 3A). However, when subjected
to four consecutive days of downhill running, the perfor-
mance of MKO mice was significantly reduced already after
the second day of running (Figure 3B), suggesting that MKO
mice are more susceptible to eccentric contraction-induced
muscle injury. This was supported by histological analyses of
soleus and gastrocnemius muscles 48 h after the last day of
treadmill running, which revealed the presence of fibres with
centralized nuclei in MKO mice, a sign of regeneration (Figure
3C). In addition, TEM of soleus muscle showed Z-line irregu-
larities in MKO mice, while WT controls had normal Z-lines
and sarcomere structure (Figure 3C). In contrast, Evans blue
staining did not show signs of membrane damage in either
MKO or WT muscle (data not shown). To determine the
effect of eccentric contractions in vitro, specific isometric
force was measured before and after 10 cyclic eccentric
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contractions of the fifth toe EDL muscle (Figure 3D). As ex-
pected, it was reduced in MKO muscle compared with WT
(Figure 3D and 3E). However, MKO and WT muscle showed
similar reductions in isometric force after repetitive eccentric
exercise, suggesting a similar intrinsic susceptibility to high
stress.
Myopalladin does not affect muscle regenerative
capacity and is not involved in muscle wasting
To determine the ability of MKO muscle to regenerate follow-
ing injury, necrosis was induced by BaCl2 injection into TA
muscle after which the muscle regeneration process was
Figure 2 Muscle performance in 10-week-old MKO and WT mice. (A–E) Data from ex vivo mechanical experiments. See also Supporting Information,
Figure S3A. (A, C) Force–velocity relations obtained from EDL (A) and soleus (SOL) (C) muscles. (B, D) Force–power relations obtained from the same
data as in (A) and (C), respectively. Solid (WT) and dashed (MKO) lines are Hill’s hyperbolic equations fit to the data. Inserts in (A–D), force–velocity and
force–power relations with force expressed as relative to its own specific isometric force at each condition. (E) Mechanical parameters during isometric
contraction and isotonic shortening of EDL and soleus muscles. Isometric contraction parameters: T0, isometric force; L0, muscle length at the plateau of
the force–length relation; w, muscle wet weight; CSA, calculated muscle cross-sectional area. Isotonic shortening parameters: V0, a/T0 and b are pa-
rameters of Hill’s hyperbolic equation interpolated to the pooled data in (A) (EDL) and (C) (soleus); Wmax, maximum power obtained with a load of
~1/3·T0. (F–J) Data from single skinned muscle fibres. See also Supporting Information, Figure S3B. (F, H) Half-sarcomere strain–isometric force (Y0–
T0) relation obtained from fibres of EDL (F) and soleus (H) muscles. Solid (WT) and dashed (MKO) lines are linear regressions fit to the data. The pa-
rameters of the regressions [slope (Cf) and ordinate intercept (s0)] are reported in (J). (G, I) Force–pCa relations obtained from fibres of EDL (G) and
soleus (I) muscles. Solid (WT) and dashed (MKO) lines are Hill’s sigmoidal equations fit to the data. The parameters of the Hill sigmoidal equation (steep-
ness, n and Ca-sensitivity, pK) are reported in (J). (J) Mechanical parameters during isometric contraction of single fibres from EDL and soleus muscles.
(E, J) The numbers of samples used are shown in brackets. (K) Passive mechanical properties of single fibres from TA and soleus (SOL) muscles from
MKO (n = 7) and WT (n = 8) mice. The protocol was performed in triplicate. Data are represented as mean ± SEM except for CSA in (F), which is rep-
resented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
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followed histologically. MKO muscle regenerated normally
(Figure 4A), although the CSA of regenerating fibres in MKO
mice took more time to reach the CSA of the control leg (Fig-
ure 4B and Supporting Information, Figure S4). The number of
nuclei in regenerating fibres was similar in BaCl2-injected MKO
and WT muscles, consistent with a role of MYPN in myofibre
growth, but not its formation (Figure 4C and Supporting Infor-
mation, Figure S4).
To determine whether MYPN may be involved in muscle
wasting, we studied the effect of sciatic nerve denervation.
As shown in Figure 4D and 4E, the reduction in TA muscle
CSA after 14 days of denervation was similar in MKO and WT
mice, although the initial CSA was smaller in MKO mice. Thus,
MYPN does not appear to play a major role in muscle wasting.
Reduced myotube width in primary myoblast
cultures derived from myopalladin knockout mice
To determine whether the defective myofibre growth in MKO
mice was intrinsic to muscle cells, primary myoblasts were iso-
lated from neonatal MKO and WT mice and studied in vitro.
While myoblast proliferation rate and fusion index were simi-
lar in MKO and WT cultures (Figure 5A–C), myotube width
was reduced by 36% in MKO cultures 24 h after induction of
differentiation (Figure 5A and 5D), consistent with the reduced
myofibre CSA in MKO mice. In support of a role of MYPN
during myoblast differentiation, a 2.5-fold increase in mRNA
levels of both MYPN and the highly homologous PALLD 200
kDa isoform was observed 24 h after induction of differentia-
tion (Figure 5E). In contrast, mRNA levels of the other major
PALLD isoforms were either unaltered (140 kDa isoform) or re-
duced (90–92 kDa isoform). At the protein level, MYPN and
the 90–92 kDa PALLD isoform were expressed at similar levels
in proliferating and differentiation cells, while protein expres-
sion levels of PALLD 200 and 140 kDa isoforms were reduced in
differentiating cells. Interestingly, in myogenic C2C12 cells,
MYPN was absent during proliferation, while both RNA and
protein expression of MYPN dramatically increased during dif-
ferentiation (Supporting Information, Figure S5A and S5B). The
expression of MYPN in proliferating primary myoblasts may be
due to some degree of activation of the differentiation pro-
gramme. mRNA levels of both the PALLD 200 and 140 kDa iso-
forms were significantly reduced both in proliferating and
differentiating MKO cells compared with WT cells, whereas
levels of the PALLD 90–92 kDa isoform were increased in pro-
liferating MKO myoblasts, which was also partly reflected at
the protein level (Figure 5G). Conversely, increased mRNA
levels of PALLD 200 and 140 kDa isoforms were observed in
C2C12 cells overexpressing MYPN (Supporting Information,
Figure S5C).
To further study the role of MYPN in myogenic differentia-
tion, we determined mRNA (Figure 5F) and protein levels (Fig-
ure 5G) of myogenic markers (Pax7, MyoD, Myf5, and
Figure 3 Exercise capacity of 10-week-old MKO and WT mice. (A) Time to exhaustion by uphill and downhill running on a treadmill (n = 10 per group).
(B) Time to exhaustion by downhill running for four consecutive days. (C) Left, haematoxylin and eosin stainings of gastrocnemius and soleus muscles
obtained 48 h after the end of the 4 day running protocol showing centralized nuclei (black arrows) in MKO mice. Right, TEM of soleus muscle obtained
at the end of the 4 day running protocol, showing severe disorganization of the Z-line (white arrows) in MKO mice. (D) Time course of isometric force
before (Pre Iso1–3), during (EC1–10), and after (Post Iso1–3) cyclic eccentric exercise (EC) (demarcated by dashed lines) of EDL muscle (n = 6 per group).
(E) Isometric force before and after EC. (F) Per cent decrease in isometric force after EC. Data are represented as mean ± SEM. *P< 0.05, ***P< 0.001;
Student’s t-test in (A, D, E, and F) and two-way ANOVA in (B).
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myogenin). Myog mRNA levels were strongly reduced both in
proliferating and differentiating MKO cells (Figure 5F), resulting
in a 37% reduction in myogenin expression in differentiating
MKO cells (Figure 5G). Also, Myod1 mRNA levels were reduced
both in proliferating and differentiating MKO cells, while Pax7
levels were decreased andMyf5 levels increased in proliferating
cells, although they were not significantly altered at the protein
level (Figure 5F and 5G). Conversely, Pax7, Myod1, and Myog
were increased in MYPN-overexpressing C2C12 cells
(Supporting Information, Figure S5C). Taken together, these re-
sults suggest that delayed myoblast differentiation rather than
defective myoblast fusion is responsible for the smaller
myofibre CSA of MKO mice.
Western blot analyses for total and phosphorylation levels
of various proteins involved in muscle growth and turnover
revealed no significant changes (Supporting Information, Fig-
ure S5D). Because muscle cell size represents a balance be-
tween protein synthesis and degradation, we measured
puromycin incorporation30 and levels of poly-ubiquitinated
proteins after treatment with the proteasome inhibitor
MG262. As shown in Figure 5H and 5I, a decreased amount
of puromycin-labelled peptides and an increased amount of
ubiquitinylated peptides were observed in MKO cultures, indi-
cating decreased protein synthesis and increased protein deg-
radation in MKO cultures.
RNA-sequencing reveals abnormal serum response
factor signalling in myopalladin knockout mice
To dissect the molecular mechanisms responsible for the re-
duced myofibre CSA in the skeletal muscle of MKO mice,
RNA-Sequencing (RNA-Seq) analyses were performed on TA
muscle from 2- to 4-week-old MKO mice and WT littermates;
191 genes were significantly down-regulated and 131 genes
significantly up-regulated (Figure 6A and Supporting Informa-
tion, Tables S3 and S4). Hierarchical clustering of significantly
modulated genes revealed a data set of 24 commonly down-
Figure 4 Myopalladin does not affect muscle regenerative capacity and is not involved in muscle wasting. (A) Representative hemaetoxylin and eosin
stainings of TA muscle from 10-week-old MKO and WT mice at different time points after BaCl2 injection. (B) Myofibre CSA of BaCl2-injected muscle vs.
control muscle (Ctrl) 10 and 21 days (d) after injection. (C) Number of nuclei in newly formed fibres (containing centralized nuclei) 21 days after BaCl2
injection. (D) Myofibre CSA of different fibre types in denervated (Den) TA muscle vs. Ctrl muscle from 10-week-old MKO and WT mice. (E) Per cent
reduction in CSA after denervation. (B–E) Data are represented as mean ± SEM (n = 3 per group). *P < 0.05; Student’s t-test.
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Figure 5 Reduced myotube width in primary MKO myoblast cultures. (A) Top, representative light microscopy images of primary myoblast cultures de-
rived from MKO and WT mice during proliferation (Prol) and 24 h after induction of differentiation (Diff). Below, immunofluorescence staining for α-
actinin-2 (red) and desmin (green). Nuclei are visualized by DAPI (blue). (B) Myoblast proliferation rate as measured by percentage EdU incorporation
(>2200 nuclei analysed per replicate). (C) Fusion index as indicated by the percentage of myotubes containing three or more nuclei (>2500 nuclei
analysed per replicate). (D) Quantification of myotube width of arbitrarily selected myotubes using ImageJ (>250 myotubes per replicate), showing re-
duced myotube width in MKO cultures. (E, F) qRT-PCR analysis on proliferating (Prol) and differentiating (Diff) myoblasts from MKO and WT mice for
(E)Mypn and Palld isoforms, and (F) myogenic markers.Gapdhwas used for normalization. In (B–F), n = 3 per group from three independent experiments.
(G) Western blot analysis for MYPN, PALLD, and myogenic markers. The blots are representatives of three replicates per group. GAPDHwas used as load-
ing control. Densitometric analyses are shown on the right. (H) Assessment of protein synthesis by western blot analysis for puromycin-labelled proteins
following puromycin-treatment of cells (left) and protein degradation by western blot analysis for poly-ubiquitinated proteins following MG262-treat-
ment (right). The blots are representatives of three replicates per group. GAPDHwas used as loading control. (I) Assessment of protein synthesis and pro-
tein degradation by densitometric analysis of puromycin-labelled (Puro) proteins and poly-ubiquitinated (Poly-Ub) proteins, respectively. Data are
represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test in (B, C, and D) and two-way ANOVA in (E, F, G, and I).
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regulated genes at both time points involved in muscle con-
traction, muscle development, and myofibril assembly, and
24 commonly up-regulated genes implicated in myofibril as-
sembly and muscle contraction as well as actomyosin struc-
ture organization (Figure 6A and 6B). Ingenuity Pathway
Analysis identified SRF as the upstream regulator of many of
the down-regulated genes (Figure 6C), including actin iso-
forms (Acta1, Acta2, and Actc1) and various other SRF target
genes, such as Pdlim7, Ctgf,Myl9, Igfbp6, Igfn1, and Fhl2 (Fig-
ure 6D). Among the most up-regulated genes were the sarco-
meric proteins Sln, Pak1, Ankrd1, and Ankrd2. Selected RNA-
Seq results were confirmed by qRT-PCR (Figure 6E). In addi-
tion, qRT-PCR for Palld isoforms revealed reduced levels of
transcripts encoding PALLD 200 and 90–92 kDa isoforms in
MKO muscle (Figure 6E). To further identify the signalling
pathways affected by MYPN ablation, we performed western
blot analyses for MYPN interaction partners and proteins in-
volved in muscle metabolism (Figure 6F and Supporting Infor-
mation, Figure S6). Consistent with the up-regulation of Pak1
in MKO mice, p21-activated kinase 1 (PAK1) was 2.0-fold and
2.4-fold up-regulated in TA muscle of 4- and 8-week-old MKO
mice, respectively, while no changes in its phosphorylation
level or the expression of its upstream effectors Cdc42 and
Rac1/2/3 were observed (Supporting Information, Figure
S6). Unexpectedly, increased Akt phosphorylation was ob-
served in the muscle of 4-week-old MKO mice, while phos-
phorylation levels of the Akt downstream targets P70 S6
kinase, 4E-BP1, and GSK3β were similar in MKO and WT mus-
cle (Supporting information, Figure S6). Additionally, the
mitogen-activated protein kinases Erk1/2 and JNK were up-
regulated in MKO muscle (Figure 6F). RNA-Seq showed no in-
crease in the expression of ubiquitin ligases, such as Atrogin1/
Fbx032 and Murf1/Trim63 in MKO mice, suggesting that the
reduced CSA is not due to protein degradation through activa-
tion of the ubiquitin-protease pathway.
Myopalladin binds and bundles filamentous actin
in vitro
The SRF signalling pathway is regulated by changes in actin dy-
namics altering the intracellular ratio between globular (G-ac-
tin) and filamentous actin (F-actin), regulating the nuclear
accumulation of the SRF coactivator myocardin-related tran-
scription factor A (MRTF-A).46 In particular, upon actin polymer-
ization, MRTF-A, which is sequestered in the cytoplasm through
binding to G-actin, gets released and translocates to the nucleus
where it binds and activates SRF. PALLD binds and bundles F-
actin through its Ig3 domain, homologous to the MYPN Ig3 do-
main, and more strongly with a fragment containing Ig3 and Ig4
(Ig3–4),40 thereby stabilizing actin and promoting actin poly-
merization and bundling.47 Based on the reduced SRF activity
in MKO muscle and the high homology of MYPN with PALLD,
we hypothesized that MYPN plays a similar role in modulating
the actin cytoskeleton. To determine whether MYPN, like
PALLD, can bind directly to F-actin, we performed actin co-
sedimentation assays with MYPN Ig3, Ig4, and Ig3–4 domains.
The MYPN Ig3 domain co-sedimented with F-actin with a disso-
ciation constant (Kd) of 7.6 ± 1.6 μM, while the MYPN Ig4 do-
main did not bind to F-actin (Figure 7A). The tandem Ig3–4
domain had only slightly increased binding affinity (Kd MYPN
Ig3–4 = 4.6 ± 2.1 μM), which is in contrast to the PALLD Ig3–4
domain, which greatly increases F-actin binding (Kd = 9 ± 2
μM) compared with the PALLD Ig3 domain alone (Kd = 60–80
μM).40 Thus, the MYPN Ig3 domain exhibits a higher binding af-
finity towards F-actin compared with PALLD, which is not fur-
ther increased by the presence of the Ig4 domain.
To determine whether MYPN can also crosslink actin fila-
ments, the co-sedimentation assay was repeated with an ad-
ditional low speed spin to pellet bundled F-actin. In the
absence of MYPN, F-actin was essentially absent from the
low speed pellet, whereas a significant amount of F-actin
was detected in the presence of MYPN Ig3 or Ig3–4 domains,
demonstrating the ability of MYPN to crosslink F-actin (Figure
7B). The presence of actin bundles was confirmed by confocal
microscopy, showing dose-dependent actin bundle formation
in the presence of the MYPN Ig3 domain (Figure 7C). F-actin
bundling efficiency was not increased by the presence of
the MYPN Ig4 domain, indicating that the MYPN Ig3 domain
is sufficient for maximal crosslinking.
To monitor the effect of MYPN on actin polymerization, we
measured the rate and degree of polymerization of pyrene-
labelled actin in the presence or absence of various concen-
trations of MYPN Ig3 domain (Figure 7D). In contrast to
PALLD, which promotes actin polymerization,47 the actin poly-
merization rate was decreased in a dose-dependent manner
in the presence of MYPN Ig3 domain (Figure 7D and 7E). Un-
fortunately, it was not possible to reliably perform the
pyrene-actin polymerization assay with the MYPN Ig3–4 tan-
dem domain, which appears to alter the intrinsic fluorescence
of pyrene actin, presumably by binding to the actin filament,
changing the environment of the pyrene. As an alternative
method for measuring actin polymerization kinetics, we
attempted to use dynamic light scattering, but these experi-
ments were complicated by F-actin bundling in the presence
of MYPN, causing an increase in light scattering, thus preclud-
ing the interpretation of effects on actin polymerization.
To determine the role of MYPN in stabilizing actin fila-
ments, we monitored the disassembly rate of pyrene-labelled
actin filaments induced by the actin monomer sequestering
agent Latrunculin A in the presence of MYPN domains. Upon
addition of MYPN Ig3 domain at a 1:2molar ratio of MYPN Ig3
domain to F-actin, the disassembly rate decreased by 80%
(Figure 7F, left). With increasing concentrations of MYPN Ig3
domain, the rate of disassembly was further reduced and at
a 1:1 ratio, the rate decreased to almost 90% compared with
F-actin alone. Similar results were observed with the MYPN
Ig3–4 tandem domain (Figure 7F, right). These results
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demonstrate that binding of MYPN to actin filaments de-
creases the disassembly of actin monomers from filaments,
thus stabilizing the filaments.
Myopalladin binds to myocardin-related
transcriptions factors
Because PALLD is known to bind to MRTF-A and MRTF-B
through its C-terminal region,48 we used the yeast two-hybrid
(Y2H) system to test whether the corresponding region of
MYPN also binds to MRTFs. As shown in Figure 8A and 8B,
the MYPN C-terminal region bound strongly to MRTF-A and
more weakly to MRTF-B. Furthermore, using truncated frag-
ments of MYPN and MRTF-A, we found that the MYPN Ig3 do-
main is sufficient for binding to MRTF-A, while the minimal
binding region in MRTF-A corresponds to residues 347–711
of MRTF-A (Acc. NM_020831.4), including the SAP domain
and the Leucine Zipper (LZ). The interaction was confirmed
by co-immunoprecipitation (Figure 8C) and colocalization
Figure 6 RNA-Sequencing (RNA-Seq) analysis reveals abnormal SRF signalling in MKO mice. (A) Heat map of unsupervised hierarchical clustering of 322
genes undergoing a change of expression (false discovery rate (FDR) ≤ 0.1; log2 count per million (logCPM) ≥0) in TA muscle from 2- to 4-week-old MKO
and WT littermate control mice, respectively (n = 3 per group). Genes that are modulated at both time points are shown. W, weeks. See also Supporting
Information, Tables S2 and S3. (B) Gene ontology analysis showing the significant (adj. P value ≤0.01) biological processes in which the commonly reg-
ulated genes are involved. (C) Ingenuity Pathway Analysis (IPA) showing the most significant upstream regulators of the modulated genes at each time
point. The list is ranked by weighted scoring (-log (adj. P value) *|Z-score|). (D) Heat map showing the fold change of SRF target genes that are down-
regulated in MKO mice. (E) qRT-PCR analysis on TA muscle from MKO and WT mice for selected transcripts confirming the RNA-Seq results (n = 4–6 per
group). Gapdh was used for normalization. (F) Western blot analysis for MYPN binding proteins and proteins involved in signalling pathways. α-Tubulin
was used as loading control. The blots are representatives of three replicates per group. See also Supporting Information, Figure S6B. (G) Densitometric
analysis for significantly changed proteins. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
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studies (Figure 8D). Immunofluorescence stainings showed no
differences in the localization of MRTF-A or other MYPN-
interacting proteins in TA muscle from MKO and WT mice
(Supporting Information, Figure S8).
Myopalladin promotes myocardin-related
transcription factor-induced serum response factor
signalling in C2C12 cells
To determine whether MYPN, like PALLD, can activate the SRF
signalling pathway, we performed SRF-luciferase reporter as-
says 48 h after cotransfection of myogenic C2C12 cells with
increasing amounts of HA-MYPN or HA-PALLD in the presence
and absence of FLAG-MRTF-A. MYPN increased MRTF-A-
mediated activation of SRF activity in a dose-dependent man-
ner (Figure 9A), which was consistent with increased Acta1
and Actc1 mRNA levels, while Mrtfa and Srf levels were unal-
tered (Figure 9B). Conversely, an SRF-luciferase assay in pri-
mary MKO and WT myoblast cultures showed reduced SRF
activity in differentiating MKO cultures (Figure 9C). Consis-
tently, the SRF target genes Acta2, Actc1, Myh4, Myl9, Mrtfa,
and Srf, which is its own target, were down-regulated in dif-
ferentiating MKO cells, and Actc1 and Myh4 also during
proliferation (Figure 9D). CARP/Ankrd1, which is also an SRF
target, was up-regulated in proliferating MKO myoblasts.
SRF is known to regulate cell growth and differentiation,46
and skeletal muscle specific deletion of SRF was reported to
result in postnatal lethality due to a failure of muscle fibres
to grow without affecting myoblast fusion.49 Therefore, to de-
termine whether decreased SRF activity may be responsible
for the reduced myofibre CSA in MKO muscle and consequent
reduced myotube width in primary MKO cultures, we infected
MKO cultures with adenovirus expressing constitutive active
SRF (SRF-VP16).28,29 This was sufficient to rescue the MKO
phenotype, resulting in similar myotube width in MKO and
WT cultures, which was increased compared with the control
cultures transduced with LacZ control virus (Figure 9E and 9F
and Supporting Information, Figure S8).
Discussion
In the present work, we studied the effect of MYPN ablation
on skeletal muscle structure and function. MKO mice had re-
duced body weight and showed decreased myofibre CSA,
partly compensated for by an increase in fibre number.
Figure 6 Continued.
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Consistently, reduced myotube width was observed in pri-
mary skeletal muscle cultures from MKO mice compared with
WT control mice. As a direct result of the reduced myofibre
CSA, isometric force and power output were reduced in
MKO EDL muscle, while the force developed by each myosin
motor, the kinetics of actin-myosin interaction, and the Ca2
+-sensitivity of the contractile apparatus were unaffected.
The smaller effect of MYPN ablation on power output in
soleus muscle compared with EDL muscle may be explained
by (i) the reduced CSA of the fast and powerful type 2B and
2X fibres in EDL muscle (Figure 1F), whereas in soleus muscle,
only the slow type 1 fibres were significantly reduced in size
(Figure 1G), and (ii) the larger increase in fibre number in so-
leus muscle (66%) compared with EDL muscle (38%) (Figure
1H), possibly explained by the higher content of satellite cells
and thus myogenic capacity of soleus muscle.50
Figure 7 The MYPN Ig3 domain binds and bundles F-actin. (A) Assessment of the binding of MYPN to F-actin by ultracentrifugation of increasing con-
centrations of F-actin with MYPN Ig3, Ig4, and Ig3–4 domains (10 μM), followed by SDS-PAGE of supernatants (S) and pellets (P). The fraction of MYPN
that co-sedimented with F-actin was determined by densitometry of the gel (n = 3), allowing for determination of Kd. Data are represented as mean ±
SEM. (B) Actin bundling assay showing that the MYPN Ig3 and Ig3–4 domains are capable of bundling F-actin. F-actin (10 μM) incubated with MYPN Ig3,
Ig4, or Ig3–4 domains (10–20 μM) was subjected to low speed centrifugation to sediment bundled F-actin. The pellet containing actin bundles (B) was
collected before sedimentation of the remaining F-actin by ultracentrifugation, whereafter SDS-PAGE was performed. B, bundled F-actin; S, superna-
tant; P, pellet. (C) Confocal images of Oregon Green-labelled actin filaments in the presence or absence of MYPN Ig3 domain at various concentrations.
(D) In vitro actin polymerization assay revealing that the MYPN Ig3 domain inhibits actin polymerization in a dose-dependent manner. Pyrene-labelled
globular actin (G-actin) (5 μM) was polymerized with MYPN Ig3 domain (2–30 μM). Polymerization was monitored by measuring the increase in fluo-
rescence intensity over time. (E) Plot of the overall actin polymerization rate (nM/s) vs. MYPN Ig3 concentration. (F) In vitro actin depolymerization
assay showing that MYPN Ig3 and Ig3–4 domains prevent F-actin depolymerization in a dose-dependent manner. Pyrene-labelled F-actin (2 μM) was
incubated with MYPN Ig3 (left) or Ig3–4 domains (right) (1–20 μM) after which depolymerization was induced by addition of Latrunculin A (LatA), while
measuring fluorescence intensity to monitor actin filament disassembly.
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RNA-Seq revealed the down-regulation of various genes in-
volved in sarcomere assembly and organization in MKO mice,
including actin isoforms and other SRF-target genes, consis-
tent with reduced SRF activity in MKO muscle. Among the
down-regulated SRF target genes were Palld isoforms, sug-
gesting that PALLD is unlikely to compensate for MYPN loss.
The effect of MYPN on the SRF pathway was confirmed by
SRF luciferase assays in myogenic cells in which we showed
that MYPN promotes MRTF-A-induced activation of SRF in a
dose-dependent manner, while MYPN ablation reduces SRF
activity. Furthermore, consistent with the hypothesis that
MYPN promotes skeletal muscle growth through activation
of the SRF pathway, transduction of MKO myoblasts with con-
stitutive active SRF rescued the reduced myotube width.
Because the SRF pathway is regulated by changes in actin dy-
namics, affecting the balance between G-actin and F-actin,46we
performed biochemical assays to determine whether MYPN,
like PALLD, plays a role in organizing the actin cytoskeleton. This
revealed that the MYPN Ig3 domain can bind and bundle F-
actin. However, unlike PALLD, which promotes actin polymeri-
zation,47 MYPN reduces the actin polymerization rate. On the
other hand, it efficiently stabilizes F-actin, even more strongly
than PALLD, preventing its depolymerization. These results are
consistent with the SRF luciferase assays, showing that PALLD
activates SRF more strongly than MYPN, activating SRF both in
the presence and absence of exogenous MRTF-A (Figure 9A).
Like PALLD,48 we found that MYPN binds to MRTF-A and
MRTF-B and colocalizes with MRTF-A both in the sarcomere
and the nucleus, suggesting that MYPN and PALLD may di-
rectly affect the shuttling of MRTFs between the cytoplasm
and the nucleus. Both proteins bind to the central region of
MRTF-A, comprising the SAP and LZ domains. The LZ motif al-
lows homodimerization and heterodimerization with
myocardin and other MRTFs, while SAP domains have been
implicated in chromosomal dynamics, nuclear organization,
and apoptosis.46 In particular, the MRTF-A SAP domain has
been implicated in both SRF-dependent and SRF-independent
transcription of genes involved in cell proliferation, migration,
and metastasis.51 In summary, by stabilizing F-actin and possi-
bly through its binding to MRTFs, MYPN activates SRF, provid-
ing a molecular mechanism for the reduced myofibre CSA in
MKO mice (Figure 10). The significance of the binding of
MYPN and PALLD to MRTFs will be subject to future studies.
RNA-Seq analysis revealed a number of genes that were
highly up-regulated in MKO EDL muscle, including Sln,
Ankrd1, and Pak1. SLN regulates SERCA activity and promotes
mitochondrial biogenesis and oxidative metabolism in re-
sponse to increased energy demand, improving endurance
and muscle performance.52 SLN has been reported to be up-
regulated in mouse models of Duchenne muscular dystrophy
and various myopathies,53 suggesting that SLN up-regulation
may be a general response to increased metabolic demand
Figure 8 The MYPN Ig3 domain binds to myocardin-related transcription factors (MRTFs). (A, B) Yeast-two hybrid (Y2H) assay showing binding of the
MYPN Ig3 domain to MRTF-A residue 347–611, comprising the SAP and LZ domains. MYPN binds less strongly to MRTF-B. (A) The domain structure of
MRTF-A is shown with the constructs that were tested for binding to MYPN in the Y2H system below. RPEL, conserved N-terminal domain; ++, basic
domain; Q, glutamine-rich domain; SAP, SRF-A/B-Acinus-PIAS domain, LZ, leucine zipper-like domain, TAD, transactivation domain. (B) Culture plate
with the different combinations of Y2H cotransformations as shown in the table on the left. (C) Co-immunoprecipitation (Co-IP) assay with anti-HA an-
tibody after transfection of HEK293 cells with HA-tagged MYPN constructs and FLAG-tagged MRTF-A, confirming the binding of MYPN to MRTF-A. The
experiment was repeated three times. (D) Immunofluorescence analysis of TA muscle electroporated with PmCherry-N1-MYPN (red) and stained for
MRTF-A (green), showing colocalization in the sarcomere and nucleus. Nuclei are visualized by DAPI (blue).
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Figure 9 MYPN promotes SRF signalling. (A) SRF-luciferase reporter assays in C2C12 cells, demonstrating that MYPN and PALLD increase MRTF-A-in-
duced activation of SRF activity in a dose-dependent manner. Cells were cotransfected with Acta2 luciferase reporter and expression vectors encoding
MYPN or PALLD in increasing amounts in the absence (left; 50, 100 ng of MYPN or PALLD) or presence (right; 10, 25, 50 ng of MYPN or PALLD) of MRTF-
A (3 ng). (B) qRT-PCR on C2C12 cells 2 and 3 days after transfection with MYPN or control vector and induction of differentiation (Diff), showing up-
regulation of SRF target gene expression in MYPN-overexpressing cells. Gapdh was used for normalization. (C) SRF luciferase reporter assay in primary
myoblast cultures derived from MKO and WT mice performed 24 h after adenoviral infection with Acta2 luciferase reporter and Renilla standardization
reporter plasmids and induction of differentiation. AdLacZ was used as control. (D) qRT-PCR on proliferating (Prol) and differentiating (Diff) myoblasts
from MKO and WT mice, showing down-regulation of SRF target gene expression in MKO cultures. Gapdh was used for normalization. (E) Represen-
tative light microscopy images (top) and immunofluorescence stainings (bottom) for α-actinin-2 (red) of primary myoblast cultures derived from
MKO and WT mice 40 h after infection with Ad-SRF-VP16 (expressing constitutive active SRF) or Ad-LacZ and induction of differentiation. Nuclei are
visualized by DAPI (blue). See also Supporting Information, Figure S8. (F) Quantification of myotube width of arbitrarily selected myotubes using ImageJ
40 h after infection with Ad-SRF-VP16 or AdLacZ (n> 130myotubes per replicate), showing rescue of reduced myotube width in MKO cultures infected
with Ad-SRF-VP16. Three replicates per group from three independent experiments were analysed. Data are represented as mean ± SEM. *P < 0.05,
**P < 0.01, ***P < 0.001; Student’s t-test in (C) and two-way ANOVA in (B, D, and F).
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under conditions of compromised muscle function to
improve oxidative metabolism. Although CARP/Ankrd1 is a
target of SRF, its transcript levels were up-regulated both in
MKO muscle and primary cells, while it was unaltered at the
protein level. It is possible that the up-regulation may be re-
lated to its interaction with MYPN and general induction in
conditions of stress.54 PAK1 expression was increased in
MKO muscle both at the RNA and protein level, while the
PAK1 phosphorylation level was unchanged. PAK1 plays an
important role in the regulation of actin cytoskeletal dynam-
ics55,56 and has been shown to promote myoblast differentia-
tion and muscle regeneration as well as counteract muscle
atrophy during cancer cachexia.57,58 Thus, the up-regulation
of PAK1 is not likely to contribute to the reduction in
myofibre CSA in MKO mice and may be a compensatory re-
sponse to the reduced SRF signalling in MKO mice. The unex-
pected activation of Akt and the mitogen-activated protein
kinases ERK and JNK in MKO mice, which all promote muscle
growth,59,60 may likewise be a compensatory response to
counteract the reduced myofibre CSA or simply due to de-
layed growth of MKO mice (except for ERK, they are only
up-regulated in 4-week-old MKO mice).
The MKOmouse model is particularly relevant in light of the
recent identification of biallelic loss-of-function mutations as-
sociated with NM,11 cap myopathy,10 and congenital myopa-
thy with hanging big toe and ultrastructural changes,
including Z-line fragmentation and disruption of the regular
square pattern of the Z-line, possible early manifestations of
Z-line destabilization.12 TEM of MKO muscle showed normal
sarcomere organization without nemaline rod bodies or caps.
However, MKO mice developed progressive Z-line widening
from 8 months of age. Furthermore, after downhill running,
we observed Z-line streaming and regenerating myofibres with
centralized nuclei in MKO muscle, while no damage or signs of
regeneration were present in WT mice subjected to the same
exercise protocol. Thus, MYPN is important for
the maintenance of Z-line integrity during aging and in re-
sponse to exercise, suggesting that exercise may aggravate
the disease in patients carrying biallelic MYPN mutations. In-
creased muscle damage in MKO mice was consistent with de-
creased exercise capability of MKO mice already from the
second day of downhill running. On the other hand, the reduc-
tion in isometric force after repetitive eccentric contractions
in vitro was similar in MKO and WT mice. The increased injury
of MKO mice after downhill running may be due to the fact
that MKO muscle generate less absolute force compared with
WT muscle and thus must be activated to a higher relative
level than WT muscle to achieve the same absolute force re-
quired for locomotion, thus resulting in higher injury.61
The phenotype of the MKO mice is distinct from the pheno-
type of homozygous knock-in mice, carrying the MYPN p.Q526X
nonsense mutation (MYPNQ526X),62 equivalent to the human
c.1585C > T mutation, which is causative for RCM. While het-
erozygous MYPNQ526X mice express a truncated 65 kDa MYPN
protein and develop RCM, recapitulating the human disease,
homozygous MYPNQ526X mice show impaired MYPN transcrip-
tion and were thus considered a model of MYPN gene ablation.
However, in contrast to MKO mice, MYPNQ526X mice did not ex-
hibit reduced myofibre CSA and did not appear to show muscle
weakness,11 although biomechanical studies have not been per-
formed to verify this. Furthermore, even though MYPNQ526X
mice had well-organized sarcomeres, some Z-line streaming
and the presence of small nemaline-like bodies reminiscent of
mild NM were reported. The discrepancy between the two
Figure 10 Working model describing how MYPN and PALLD may promote SRF signalling. The SRF coactivator MRTF-A is sequestered in the cytoplasm
through binding to G-actin and incorporation of G-actin into F-actin filaments releases MRTF-A, allowing it to translocate to the nucleus where it binds
and activates the SRF transcription factor.46 Thus, the nuclear accumulation of MRTF-A, and consequently SRF activity, is regulated by the F-actin/G-
actin ratio. MYPN inhibits actin polymerization but strongly prevents actin depolymerization, with the net result of increasing the F-actin/G-actin ratio,
stimulating the SRF signalling pathway. PALLD both promotes actin polymerization and inhibits actin depolymerization and thus has an even stronger
activating effect on the SRF pathway. Both MYPN and PALLD bind to the central region of MRTF-A, comprising its SAP and LZ domains, possibly further
affecting the localization or activity of MRTF-A.
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models suggests that the MYPNQ526X mouse model cannot be
considered a knockout model and a small amount of truncated
65 kDa MYPN protein is likely responsible for the observed phe-
notype, suggesting that truncated MYPN protein rather than
MYPN ablation is responsible for the NM phenotype. This is
consistent with the detection of 5′ MYPN mRNA transcripts
both in heart and skeletal muscle of homozygous MYPNQ526X
mice as well as a small amount of truncated 65 kDa MYPN pro-
tein in the heart of homozygous MYPNQ526X mice,62 suggesting
that trace amounts of 65 kDa MYPN protein are likely to be
present also in skeletal muscle.
Muscle weakness in NM has been associated with decreased
thin filament length, reduced actomyosin interaction, or altered
calcium sensitivity,63which is not the case inMKOmice in which
reduced myofibre CSA is responsible for the observed muscle
weakness. Considering that patients carrying biallelicMYPNmu-
tations have strongly reducedMYPN expression and often show
fibre size variability and atrophy, it would be interesting to de-
termine whether the muscle weakness may at least partly be
due to reduced myofibre CSA and SRF signalling.
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Figure S1. Generation of myopalladin knockout mice. (A)
Targeting strategy for generation of MYPN knockout (MKO)
mice. A restriction map of the relevant genomic region of
Mypn is shown on top, the targeting construct is shown in
the middle, and the mutated locus after recombination is
shown at the bottom. The grey box indicates exon 1. Neo,
neomycin resistance gene. (B) Detection of wild-type (WT)
and targeted alleles by Southern blot analysis after digestion
with MfeI using the probe shown in (A). Het, heterozygous.
(C) Northern blot analysis showing the successful ablation of
MYPN in left ventricle (LV) and tibialis anterior (TA) muscle
from MKO and WT mice. (D) Detection of MYPN protein by
Western blot analysis. GAPDH antibody was used as loading
control.
Figure S2. Immunofluorescence and transmission electron
microscopy analysis of MKO mice. (A) Examples of immuno-
fluorescence stainings for myosin heavy chain isoforms
(MHC 2A, 2B, and all MHC isoforms except 2X; green) and
laminin (red) on cryosectioned extensor digitorum longus
(EDL) and soleus (MHC 1) muscle. (B) Low magnification trans-
mission electron micrographs from EDL muscle of 8-month-
old MKO and WT mice showing normal sarcomere organiza-
tion.
Figure S3. Mechanical methods. (A) Sample record of length
change (lower trace) during isotonic contraction against a
load of 0.5 T0 (upper trace) from WT EDL muscle. The vertical
line indicates the stimulus start. Inset, sample records of
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length changes during isotonic contraction against different
loads as indicated by the values close to the traces. (B) T1 re-
lations for four pCa values obtained from a single fiber of a
WT EDL muscle. The relations were obtained by plotting the
extreme force attained at the end of the length step, T1 (rel-
ative to T0 at pCa = 4.50) vs. the length step amplitude. Inset,
force response (lower trace) to a length step release of 1 nm
(upper trace) at pCa = 4.50 (horizontal line below force re-
sponse, force baseline).
Figure S4. Immunofluorescence analysis following BaCl2 in-
jection in mouse TA muscle from MKO and WT mice. Repre-
sentative laminin (red) and DAPI (blue) stainings of
cryosectioned TA muscle from BaCl2-injected muscle vs. con-
trol (Ctrl) muscle 10 and 21 days after injection of MKO and
WT mice.
Figure S5. qRT-PCR and western blot analyses on C2C12 cells
and primary myoblast cultures derived from MKO and WT
mice. (A) qRT-PCR analysis for Mypn on C2C12 cells during
proliferation and at different stages following induction of dif-
ferentiation. β-actin was used for normalization (n = 3 per
group from 3 independent experiments). Data are repre-
sented as mean ± SEM. ***P < 0.001 vs. day 0 of differentia-
tion; ANOVA. (B) Western blot and densitometric analysis for
MYPN on C2C12 cells during proliferation and at different
stages following induction of differentiation. The blot is repre-
sentative of 3 replicates per group. β-actin was used as load-
ing control. Data are represented as mean ± SEM. ***P <
0.001 vs. day 0 of differentiation; one-way ANOVA. (C) qRT-
PCR on C2C12 cells 2 and 3 days after transfection with MYPN
or control vector for quantification of levels ofMypn and Palld
transcripts, encoding the most common PALLD isoforms, as
well as myogenic markers (n = 3 replicates per group from 3
independent experiments). GAPDH was used for normaliza-
tion. Data are represented as mean ± SEM. *P < 0.05, **P
< 0.01, ***P < 0.001; two-way ANOVA. (D) Western blot
and densitometric analyses for proteins involved in muscle
growth and atrophy on cell lysate from proliferating (Prol)
and differentiating (Diff) myoblasts derived from MKO and
WT mice. The blots are representatives of 3 replicates per
group from 3 independent experiments. GAPDH was used as
loading control. Data are represented as mean ± SEM. *P <
0.05; **P < 0.01; ***P < 0.001; two-way ANOVA.
Figure S6. Western blot analysis on TA muscle from MKO
and WT mice. (A) Western blot analyses on TA muscle lysate
from 4- and 8-week-old MKO and WT littermate control mice
for MYPN-interacting proteins and proteins involved in mus-
cle signaling pathways. α-Tubulin was used as loading control.
The blots are representatives of 3 replicates per group. (B)
Densitometric analysis. Data are represented as mean ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001; Student’s t-test.
Figure S7. Immunofluorescence stainings for MYPN-
interacting proteins on TA muscle from 10-week-old MKO
and WT mice. DAPI is shown in blue.
Figure S8. Efficient Ad-SRF-VP16 infection of myoblasts.
Fluorescence microscopy picture of primary myoblast cultures
40 hours after infection with Ad-SRF-VP16 and induction of
differentiation, showing that the cells were efficiently in-
fected. DAPI is shown in blue.
Table S1. Oligos used for qRT-PCR and clonings.
Table S2. Antibodies used for Western blot analysis and
immunostainings.
Table S3. List of differentially expressed genes in tibialis an-
terior (TA) muscle from 2-week-old myopalladin knockout
(MKO) vs. wild-type (WT) mice resulting from RNA-sequenc-
ing analyses.
Table S4. List of differentially expressed genes in tibialis an-
terior (TA) muscle from 4-week-old myopalladin knockout
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